Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: A prospective study

Reproductive Health

Volumn 11, Issue 1, 2014, Pages

  Hernandez Juarez, Jesus ^a,b   Garcia Latorre, Ethel A ^b   Moreno Hernandez, Manuel ^a   Moran Perez, Jose Fernando ^c   Rodriguez Escobedo, Miguel Angel ^c   Cogque Hernandez, Gerardo ^a   Julián Nacer, Rubén ^a   Hernandez Giron, Xochitl ^a   Palafox Gomez, Rosalia ^a   Isordia Salas, Irma ^a   Majluf Cruz, Abraham ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c Centro de Salud Urbano Tehuacan   (Mexico)

Author keywords

Cambios metab licos; Contracepci n; Contraception; Contraceptive skin patch; Efectos metab licos; Implante contraceptivo subd rmico; Metabolic changes; Metabolic effects; Parche cut neo anticonceptivo; Subdermal contraceptive implant

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE; BILIRUBIN; C PEPTIDE; C REACTIVE PROTEIN; CONTRACEPTIVE AGENT; CREATININE; ETHINYLESTRADIOL; ETONOGESTREL; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTATE DEHYDROGENASE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORELGESTROMINE; SOMATOMEDIN C; UNCLASSIFIED DRUG; UREA; URIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; DESOGESTREL; NORELGESTROMIN; NORGESTREL; OXIME;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ARTICLE; ATHEROGENESIS; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CONTRACEPTIVE PATCH; CONTRACEPTIVE SKIN PATCH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INDIGENOUS PEOPLE; LIVER FUNCTION TEST; LONGITUDINAL STUDY; MASTALGIA; MESTIZO; METABOLIC REGULATION; MEXICO; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SIDE EFFECT; SKIN ALLERGY; SUBDERMAL CONTRACEPTIVE IMPLANT; THYROID FUNCTION TEST; TRANSDERMAL PATCH; UTERUS BLEEDING; VAGINA BLEEDING; WEIGHT GAIN; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; LIPID METABOLISM; METABOLISM;

ADIPONECTIN; ADULT; C-PEPTIDE; C-REACTIVE PROTEIN; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; LIPID METABOLISM; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MEXICO; NORGESTREL; OXIMES; THYROID FUNCTION TESTS; TRANSDERMAL PATCH; WEIGHT GAIN;

EID: 84901980379     PISSN: None     EISSN: 17424755     Source Type: Journal    
DOI: 10.1186/1742-4755-11-33     Document Type: Article

References (42)

1. Cardiovascular Disease and Steroid Hormone Contraception. Report of a WHO Scientific group. World Health Organization, World Health Organ Tech Rep Ser 1998 877 1 89
2. Estadísticas generales. Instituto Nacional de Estadística, Geografía e Informática. Mexico, http://dgcnesyp.inegi.gob.mx
3. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicentre, dose-response study. Dittrich R, Parker L, Rosen JB, Shangold G, Creasy GW, Fisher AC, Ortho Evra/Evra 001 Study Group, Am J Obstet Gynecol 2002 186 15 20 10.1067/mob.2002.118844 11810078 (Pubitemid 34093733)
4. Evra transdermal patch. Summary of product characteristics. Janssen-Cilag International NV, http://www.janssen-cilag.co.uk/product/pdf/spc/00121.pdf
5. Pharmacokinetic overview of Ortho EvraTM/EvraTM. Abrams LS, Skee D, Natarajan J, Wong FA, Fertil Steril 2002 77 Suppl 1 3 S12
6. Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches. Abrams LS, Skee DM, Wong FA, Anderson NJ, Leese PT, J Clin Pharmacol 2001 41 1232 1237 10.1177/00912700122012788 11697756 (Pubitemid 32983222)
7. Pharmacokinetics of a contraceptive patch (EvraTM/Ortho EvraTM) containing norelgestromin and ethinyloestradiol at four application sites. Abrams LS, Skee D, Natarajan J, Wong FA, Anderson GD, J Clin Pharmacol 2001 53 141 146 (Pubitemid 34264268)
8. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW, ORTHO, EVRA/EVRA 004 Study Group, JAMA 2001 285 2347 2355 10.1001/jama.285.18.2347 11343482
9. Mechanisms that explain the contraceptive action of progestin implants for women. Croxatto HB, Contraception 2002 65 21 27 10.1016/S0010-7824(01)00294- 3 11861052 (Pubitemid 34175235)
10. Clinical trial with 3-keto-desogestrel subdermal implants. Diaz S, Pavez M, Moo-Young AJ, Bardin CW, Croxatto HB, Contraception 1991 44 393 408 10.1016/0010-7824(91)90030-J 1756627
11. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Davies GC, Feng LX, Newton JR, Van Beek A, Coelingh-Bennink HJ, Contraception 1993 47 251 261 10.1016/0010-7824(93)90042-6 8462316 (Pubitemid 23107285)
12. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Makarainen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H, Fertil Steril 1998 69 714 721 10.1016/S0015-0282(98) 00015-6 9548163 (Pubitemid 28188469)
13. The pharmacodynamics and efficacy of Implanon. An overview of the data. Croxatto HB, Makarainen L, Contraception 1998 58 Suppl 2 91S 97S 10095979 (Pubitemid 29095938)
14. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM, Fertil Steril 2009 91 1646 1653 10.1016/j.fertnstert. 2008.02.140 18423453
15. Genetic structure of autochtonous populations of Meso-America: Mexico. Lisker R, Ramírez E, Babinsky V, Human Biol 1996 68 395 404 8935320 (Pubitemid 126448365)
16. Safety evaluation of a transdermal contraceptive system with an oral contraceptive. Radowicki S, Skórzewska K, Szlendak K, Ginekol Pol 2005 76 884 889 16566363
17. The effects of transdermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thai women. Kiriwat O, Petyim S, Gynecol Endocrinol 2010 26 361 365 10.3109/09513590903511455 20050766
18. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M, Obstet Gynecol 2008 11 278 284 (Pubitemid 351653416)
19. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Fleischer K, van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM, Thromb Res 2009 123 429 435 10.1016/j.thromres.2008.04.022 18829069
20. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW, Fertil Steril 2002 77 Suppl 1 19 S26
21. ORTHO EVRA/EVRA 002 Study Group: Efficacy and safety of a transdermal contraceptive system. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy W, Obstet Gynecol 2001 98 799 805 10.1016/S0029-7844(01)01534-4 11704172 (Pubitemid 33042548)
22. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D, J Pediatr Adolesc Gynecol 2005 18 85 90 10.1016/j.jpag.2004. 11.016 15897103 (Pubitemid 40719250)
23. Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women. Vieira CS, Ferriani RA, Garcia AA, Gomes MK, Azevedo GD, de Sá MF S, Thromb Haemost 2005 94 682 683 16268492 (Pubitemid 41300872)
24. Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. Egberg N, van Beek A, Gunnervik C, Hulkko S, Hirvonen E, Larsson-Cohn U, Bennink HC, Contraception 1998 58 93 98 10.1016/S0010-7824(98)00070-5 9773263 (Pubitemid 28449362)
25. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids-a randomized comparative study. Biswas A, Viegas OA, Roy AC, Contraception 2003 68 189 193 10.1016/S0010-7824(03)00145-8 14561539 (Pubitemid 38367487)
26. Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. Merki-Feld GS, Imthurn B, Seifert B, Clin Endocrinol (Oxf) 2008 68 355 360 17854390 (Pubitemid 351257852)
27. Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests-a randomized comparative study with Norplant implants. Biswas A, Biswas S, Viegas OA, Contraception 2004 70 379 382 10.1016/j.contraception.2004.05.011 15504376 (Pubitemid 39422514)
28. Non-menstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Brache V, Faundes A, Alvarez F, Cochon L, Contraception 2002 65 63 74 10.1016/S0010-7824(01)00289-X 11861056 (Pubitemid 34175239)
29. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. Rinderknecht E, Humbel RE, J Biol Chem 1978 253 2769 2776 632300 (Pubitemid 8326483)
30. The combination of insulin-like growth factor I and insulin-like growth factor binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J, J Clin Endocrinol Metab 2000 85 1518 1524 10770191 (Pubitemid 32289494)
31. Advancing age and insulin resistance: new facts about an ancient history. Paolisso G, Tagliamonte MR, Rizzo MR, Giugliano D, Eur J Clin Invest 1999 29 758 769 10.1046/j.1365-2362.1999.00522.x 10469164 (Pubitemid 29425517)
32. Etonogestrel implant in postpartum adolescents: bleeding pattern, efficacy and discontinuation rate. Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF, Contraception 2010 82 256 259 10.1016/j.contraception. 2010.02.010 20705154
33. Effects of contraceptives on hemoglobin and ferritin. Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. World Health Organization, Contraception 1998 58 262 273 9883381
34. Metabolic effects of contraceptive implants in adolescents. Guazzelli CA, de Queiroz FT, Barbieri M, Barreiros FA, Torloni MR, Araujo FF, Contraception 2011 84 409 412 10.1016/j.contraception.2011.02.006 21920197
35. Effect of the subdermal contraceptive Etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up). Inal MM, Yildirim Y, Ertopcu K, Avci ME, Ozelmas I, Tinar S, Eur J Contracept Reprod Health Care 2008 13 238 242 10.1080/13625180802075315 18609340
36. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y, Biochem Biophys Res Commun 1999 257 79 83 10.1006/bbrc.1999.0255 10092513 (Pubitemid 29299050)
37. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Han SH, Sakuma I, Shin EK, Koh KK, Prog Cardiovasc Dis 2009 52 126 140 10.1016/j.pcad.2009.06.004 19732605
38. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Hung J, McQuillan BM, Thompson PL, Beilby JP, Int J Obes 2008 32 772 779 10.1038/sj.ijo.0803793 (Pubitemid 351670618)
39. Narrative review: The role of leptin in human physiology: emerging clinical applications. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS, Ann Intern Med 2010 152 93 100 10.7326/0003-4819-152-2-201001190-00008 20083828
40. Leptin and soluble leptin receptor levels in plasma and risk of type 2 diabetes in U.S. women: a prospective study. Sun Q, van Dam RM, Meigs JB, Franco OH, Mantzoros CS, Hu FB, Diabetes 2010 59 611 618 10.2337/db09-1343 19959759
41. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Ridker PM, Circulation 2003 107 363 369 10.1161/01.CIR.0000053730.47739.3C 12551853 (Pubitemid 36158034)
42. Inflammation in atherosclerosis. Libby P, Nature 2002 420 868 874 10.1038/nature01323 12490960 (Pubitemid 36019640)